argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

Core Insights - argenx SE has reported significant progress in its product VYVGART, with over 2,500 patients currently receiving treatment globally, and aims to expand its market presence in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [1][2] - The company is advancing its Vision 2030 strategy, targeting treatment for 50,000 patients globally and securing 10 labeled indications across its medicines by 2030 [3] Financial Performance - In Q2 2025, argenx generated global product net sales of $949 million, reflecting a 97% year-over-year growth from Q2 2024 and a 19% increase from Q1 2025 [4][18] - Total operating income for the first half of 2025 was $1.775 billion, compared to $901 million in the same period of 2024 [17] - The company reported a profit of $245 million for Q2 2025, compared to a profit of $29 million in Q2 2024, and a profit of $414 million for the first half of 2025, compared to a loss of $33 million in the same period of 2024 [20] Product Development and Pipeline - VYVGART is approved for three indications: generalized myasthenia gravis (gMG), primary immune thrombocytopenia (ITP) in Japan, and CIDP in multiple regions including the U.S. and EU [4] - The company has six registrational and six proof-of-concept readouts expected by the end of 2026, with ongoing studies in various severe autoimmune diseases [6][12] - ARGX-119 is set to advance to a registrational study in congenital myasthenic syndromes (CMS) following positive proof-of-concept data [1][12] Strategic Initiatives - argenx is focused on expanding the global opportunity for VYVGART and has launched the VYVGART SC prefilled syringe, which is expected to drive demand from new patients and prescribers [2][4] - The company has entered a strategic collaboration with Unnatural Products to enhance its discovery capabilities in the oral peptide space, reinforcing its commitment to advancing its pipeline [15] Future Outlook - The company aims to continue its investment in the Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth, with four new pipeline candidates nominated [10] - Financial guidance for combined research and development and selling, general and administrative expenses remains unchanged at approximately $2.5 billion [22]